Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
439.9 INR | +0.80% | +0.03% | -20.57% |
10/05 | NetScientific says PDS Biotech's Versamune meets endpoints | AN |
10/05 | PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- The firm trades with high earnings multiples: 26.79 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Apparel & Accessories
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.57% | 695M | C | ||
+4.59% | 144B | - | A- | |
-30.97% | 44.44B | C | ||
+13.90% | 18.47B | A | ||
+15.92% | 10.69B | B | ||
+36.76% | 9B | C | ||
+4.78% | 7.23B | C- | ||
-6.64% | 6.45B | A- | ||
+30.48% | 6.39B | B | ||
+4.82% | 5.67B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PDSL Stock
- PDSL Stock
- Ratings PDS Limited